Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions

Table 5

Comparison of 1-year and 2-year survival rates after treatment between the two groups of patients ().

Groups		1 year after treatment	2 years after treatment
Control group	50	34 (68.00)	16 (32.00)
Study group	50	44 (88.00)	27 (54.00)
		5.828	4.937
		<0.05	<0.05